Jaguar Health, Inc. (JAGX)
| Market Cap | 1.88M -70.5% |
| Revenue (ttm) | 29.57M +156.0% |
| Net Income | -34.26M |
| EPS | -179.28 |
| Shares Out | 603.13K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 102,794 |
| Open | 2.910 |
| Previous Close | 2.910 |
| Day's Range | 2.910 - 3.240 |
| 52-Week Range | 2.530 - 171.500 |
| Beta | 0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 20, 2026 |
About JAGX
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS... [Read more]
Financial Performance
In 2025, Jaguar Health's revenue was $11.51 million, a decrease of -1.52% compared to the previous year's $11.69 million. Losses were -$53.58 million, 39.2% more than in 2024.
Financial StatementsNews
Jaguar Health Earnings Call Transcript: Q1 2026
Net revenue soared 816% year-over-year in Q1 2026, driven by a major out-license deal, while strategic focus shifted to rare disease drug development. Clinical milestones and non-dilutive funding position the company for future growth.
Jaguar Health Quarterly report: Q1 2026
Jaguar Health has published its Q1 2026 quarterly earnings report on May 26, 2026.
Jaguar Health Earnings release: Q1 2026
Jaguar Health released its Q1 2026 earnings on May 26, 2026, summarizing the period's financial results.
Jaguar Health Slides: Corporate presentation
Jaguar Health has posted slides in relation to its latest quarterly earnings report, which was published on May 22, 2026.
Jaguar Health reports Q1 EPS ($13.60) vs. ($584.45) last year
Reports Q1 revenue $20.27M vs. $2.21M last year. The company said, “Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025,…
Jaguar Health Reports First Quarter 2026 Financials
Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs.
Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference
Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners Conference Company plans to file its Earnings Report on May 20, 2026 on Fo...
Jaguar says first patient from pediatric MVID entered active treatment
Jaguar Health (JAGX) announced that the first patient from the cohort of pediatric MVID patients in the pivotal MVID randomized double-blind crossover clinical trial has entered the active treatment o...
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with liquid oral crofelemer...
Jaguar Health granted extension to comply with Nasdaq bid price rule
Jaguar Health (JAGX) provided an update on the status of the Company’s listing on The Nasdaq Stock Market. On May 6, 2026, Jaguar received a decision letter from the Nasdaq…
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
SAN FRANCISCO, CA / ACCESS Newswire / May 8, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided an update on the status of the Company's listing on The Nasdaq Stock Ma...
Jaguar Health’s Napo held preliminary discussion with FDA over crofelemer
Jaguar Health (JAGX) family company Napo Pharmaceuticals announced that the company recently held a preliminary discussion with the Division of Gastroenterology at U.S. Food and Drug Administration to...
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Pediatric patients with Intestinal Failure (IF) due to MVID, an ultrarare congenital disorder with lethal natural history, that has no available therapies and needs lifelong total Parenteral Support (...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on May 6, 2026, providing details for shareholder voting and corporate governance matters.
Jaguar Health announces planned launch of Neonorm Dog
Jaguar Health (JAGX) announced the planned launch of Neonorm Dog, a new extension of the Company’s Neonorm franchise for companion animals. Neonorm Dog is designed to provide dog owners with…
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Neonorm Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide dog owners with access to a plant-based product designed to support normal stool formation, gut hydra...
Jaguar Health Proxy statement: Proxy filing
Jaguar Health filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Jaguar Health announces results from trial of crofelemer
Jaguar Health (JAGX) announced topline results from the completion of its effectiveness trial of crofelemer for the treatment of chemotherapy-induced diarrhea in dogs. The statistically significant re...
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Company Advances Towards Full FDA Approval of Crofelemer for Chemotherapy-Induced Diarrhea SAN FRANCISCO, CA / ACCESS Newswire / April 29, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today annou...
Jaguar Health granted extension to demonstrate compliance with Nasdaq bid rule
Jaguar Health (JAGX) announced that on April 24, 2026, the Company received formal notice that the Nasdaq Hearings Panel has granted Jaguar an extension through May 15, 2026, to demonstrate…
Jaguar Health announces 1-for-35 reverse stock split
Jaguar announced that it will effect a reverse stock split of its issued and outstanding voting common stock, at an exchange ratio of 1-for-35, on Thursday, April 30, 2026. The…
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common stock to begin trading on split-adjusted basis on April 30, 2026 SAN FRANCISCO, CA / ACCESS Newswire...
Jaguar Health reports acceptance of abstracts on crofelemer for ESPGHAN meeting
Jaguar Health (JAGX) family company Napo Pharmaceuticals announced the acceptance of two late breaking abstracts for the treatment of pediatric IF from MVID and SBS at the 58th Annual Meeting…
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Intestinal Failure (IF) occurs in patients with an ultrarare congenital enteropathy due to microvillus inclusion disease (MVID) and/or short bowel syndrome (SBS) Jaguar has received orphan drug design...
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
SAN FRANCISCO, CA / ACCESS Newswire / April 20, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the voting results of the Company's Special Meeting of Stockholders...